BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Expression analysis of 32Dcl3 cells expressing ASXL-MT in the presence of IL-3 or G-CSF

Dataset: Expression analysis of 32Dcl3 cells expressing ASXL-MT in the presence of IL-3 or G-CSF

[u'Recurrent mutations in ASXL1 are found in various hematological malignancies and are associated with poor prognosis. In particular,...

Registered by ArrayExpress Uploader
View Dataset

[u'Recurrent mutations in ASXL1 are found in various hematological malignancies and are associated with poor prognosis. In particular, ASXL1 mutations are frequently found in patients with hematological malignancies associated with myelodysplasia including myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia. Although loss-of-function ASXL1 mutations promote myeloid transformation, a large subset of ASXL1 mutations is thought to result in stable truncation of ASXL1. Here we demonstrate that C-terminal truncating ASXL1 mutations (ASXL1-MT) inhibit myeloid differentiation and induce MDS-like disease in mice, displaying all the features of human MDS including multi-lineage myelodysplasia, pancytopenia and occasional progression to overt leukemia. Concerning the molecular mechanisms, ASXL1-MT derepressed expression of Hoxa9 and miR-125a through inhibiting PRC2-mediated methylation of H3K27. miR-125a targeted expression of a surface receptor Clec5a, which was found to supports for myeloid differentiation. In addition, HOXA9 expression was high in MDS patients with ASXL1 mutations while Clec5a expression was generally low in MDS patients. Thus, ASXL1-MT induced MDS-like disease in mice via derepression of Hoxa9 and miR-125a, and Clec5a downregulation. Our data provide evidence for a novel axis of MDS pathogenesis (ASXL1 mutations-upregulation of HoxA9 and miR-125a-downregulation of Clec5a) and implicate both ASXL1 mutants and miR-125a as therapeutic targets in MDS. Using 32Dcl3 cells transduced with pMYs-IG (mock) and pMYs-FLAG-ASXL1-MT-IG, we compared the expression profiles of 32Dcl3 cells with mock or ASXL1-MT under G-CSF stimulation at 4 time points, including 0hr (IL-3), 2hr, 6hr and 24hrs. Total RNA was extracted by Trizol reagent (Invitrogen) according to the manufacturer\u2019s protocol. Double-stranded cDNA was synthesized from 5 \u03bcg of total RNA with oligo (dT)24 T7 primer, amplified with T7 RNA polymerase up to approximately 50 \u03bcg of cRNA, and hybridized to Affymetrix Mouse Expression array 430A, which contains 45000 probe sets for 39000 transcripts and variants from over 34000 well-characterized mouse genes (Affymetrix). After washing and staining, the arrays were scanned on the GeneChip system confocal scanner (Affymetrix). The intensity for each feature of the array was captured with Affymetrix Microarray Suite (MAS) Version 5.0 software. Gene set enrichment analysis was performed by using Gene Ontology gene sets from the Molecular Signatures Database (', {u'a': {u'href': u'http://www.broad.mit.edu/gsea/msigdb/', u'target': u'_blank', u'$': u'http://www.broad.mit.edu/gsea/msigdb/'}}, u')']

Species:
mouse

Samples:
8

Source:
E-GEOD-49117

Updated:
Dec.12, 2014

Registered:
Nov.12, 2014


Factors: (via ArrayExpress)
Sample TRANSFECTION TREATMENT
GSM119398 pMYs-FLAG-ASXL1-MT-IG treated with IL-3
GSM1193982 pMYs-FLAG-ASXL1-MT-IG treated with G-CSF for 2 hours
GSM1193983 pMYs-FLAG-ASXL1-MT-IG treated with G-CSF for 6 hours
GSM1193984 pMYs-FLAG-ASXL1-MT-IG treated with G-CSF for 24 hours
GSM1193985 pMYs-IG (mock) treated with IL-3
GSM1193986 pMYs-IG (mock) treated with G-CSF for 2 hours
GSM1193987 pMYs-IG (mock) treated with G-CSF for 6 hours
GSM1193988 pMYs-IG (mock) treated with G-CSF for 24 hours

Tags

  • axis
  • disease
  • leukemia
  • pancytopenia
  • surface

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2025 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use